Nanexa AB | MedPath

Nanexa's NEX-22 Shows Promise as Once-Monthly GLP-1 Therapy in Phase I Trial

6 months ago

• Nanexa's NEX-22, a once-monthly liraglutide formulation for type 2 diabetes, demonstrated a favorable pharmacokinetic profile and safety in a Phase I study. • The trial met all primary and secondary endpoints, showing dose linearity and no significant adverse events, positioning NEX-22 as a potential alternative to daily GLP-1 injections. • Nanexa is actively seeking licensing partners to advance NEX-22 to Phase Ib/II studies, with plans to compare it directly to Victoza and explore a 505(b)(2) regulatory pathway in the US. • With secured funding into 2026, Nanexa aims to initiate Phase Ib/II trials before the end of the year and is also progressing in its development project with Novo Nordisk.